Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories (ABT) announced its intention to separate its global Nutrition business into an independent, publicly traded company through a distribution of shares to Abbott shareholders. Upon completion, Abbott shareholders will own shares in both companies, and the Nutrition business will continue operating as part of Abbott during the separation process.
The independent Nutrition company is expected to have approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites; Abbott says it will have approximately $42 billion in sales and about 106,000 employees after the transaction. Abbott expects to complete the separation by the end of 2027, subject to customary conditions, including regulatory approvals, effectiveness of a Form 10 registration statement and final approval by Abbott’s board. The transaction is intended to qualify as tax-free for U.S. federal income tax purposes. Abbott expects the combined dividend paid by both companies to equal Abbott’s dividend at separation, and says the planned separation will not affect its 2026 guidance or its 2027 guidance it plans to provide in January. Daniel Salvadori will become CEO of the new Nutrition company.
Abbott Laboratories reported third-quarter 2026 sales of $13.013 billion, up 14.5% from $11.369 billion a year earlier; comparable sales growth was 7.0%. GAAP net earnings fell 44.1% to $920 million from $1.644 billion, and GAAP diluted earnings per share were $0.53 versus $0.94. Excluding specified items, net earnings increased 8.7% to $2.477 billion from $2.278 billion, while adjusted diluted EPS was $1.42 versus $1.30.
Abbott reaffirmed the midpoint of its full-year adjusted diluted EPS outlook and tightened the range to $5.50 to $5.55; it projects comparable sales growth of approximately 6.0% and fourth-quarter adjusted diluted EPS of $1.62 to $1.67. The company reported FDA approvals for Libre Duo and TactiFlex Duo and launched SimpleScreen CRC in September. Its board declared a quarterly dividend of $0.63 per share, payable November 16, 2026, to shareholders of record October 15, 2026.
Abbott Laboratories director John G. Stratton acquired 397 Stock Equivalent Units on September 30, 2026, at a reported price of $98.83 per share. His reported balance after the transaction was 14,499 Stock Equivalent Units, including units acquired through a dividend reinvestment feature. Director fees are credited to an account under a grantor trust established by the director; the units earn the same return as if the fees were invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
Abbott Laboratories director Patricia Paola Gonzalez received 333 stock equivalent units on September 30, 2026, at a reported $98.83 per unit, bringing her reported direct balance to 6,331 units. The units represent director fees credited to an account under a grantor trust she established; they earn the same return as if the fees were invested in Abbott shares. The units are paid in cash generally at age 65 or upon retirement from the board. The reported balance includes units acquired through a dividend reinvestment feature.
Abbott Laboratories (ABT) director Kevin T. Conroy acquired 318 Stock Equivalent Units on September 30, 2026, at a reported price of $98.83 per share. His reported balance afterward was 551 Stock Equivalent Units, including units acquired through a dividend reinvestment feature. The units represent director fees credited to a grantor trust and earn the same return as if the fees were invested in Abbott stock; payment is generally in cash at age 65 or upon retirement from the board.
Abbott Laboratories (ABT) director Nita Ahuja acquired 318 stock equivalent units on September 30, 2026, at a reported price of $98.83 per unit. Her direct balance after the transaction was 771 units, including units acquired through a dividend reinvestment feature. Director fees credited to the stock equivalent unit account are paid in cash, generally at age 65 or upon retirement from the board; the units earn the same return as if the fees were invested in Abbott shares.
Abbott Laboratories director Michael F. Roman acquired 381 stock equivalent units on September 30, 2026, at a reported $98.83 per unit. His reported balance after the acquisition was 7,166 stock equivalent units, including units acquired through a dividend reinvestment feature. Director fees are credited to the account, which earns the same return as if the fees were invested in Abbott shares; the units are paid in cash generally at age 65 or upon retirement from the board.
ABBOTT LABORATORIES (ABT) director Kevin T. Conroy reported 52,507 shares delivered or withheld for payment of exercise price or tax liability on September 23, 2026. The transaction was direct, and his reported direct holdings afterward were 81,230 shares. The reported price was $103.99 per share; no Rule 10b5-1 plan is reported.
ABBOTT LABORATORIES (ABT) officer John A. McCoy Jr., Vice President and Controller, reported share dispositions in early September 2026.
On September 2, 2026 he sold 27 common shares at $109.54 per share in a sale described as an open market or private transaction. On September 1, 2026, 52 common shares were delivered or withheld for payment of exercise price or tax liability at $110.36 per share. A separate entry shows 59 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust, described as a Profit Sharing Trust, as of September 1, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
ABBOTT LABORATORIES (ABT) executive vice president and chief financial officer Philip P. Boudreau reported a Form 4 showing that on September 1, 2026, 388 common shares were disposed of at $110.36 per share to satisfy exercise price or tax liability obligations. After this withholding, he holds 70,784 common shares directly, plus indirect holdings of 9,332 shares in the Abbott Laboratories Stock Retirement (Profit Sharing) Trust and 2,200 shares held by his spouse. No Rule 10b5-1 trading plan is affirmed.